• Significant advances in synthetic anti-infective program
• Positive data from Phase II clinical trial of lead compound R327G
• Received regulatory approvals to commence Phase 3 trials for R327G

Recce Pharmaceuticals Ltd has reported its financial results for the year ended 30 June 2025, with a focus on the significant advances made in the development of the company's synthetic anti-infective program. During the reporting period, the company successfully dosed all 30 patients in its Phase II clinical trial of R327G for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI), with positive patient data analysis showing an 86% successful clinical response after 7 days of treatment and 93% achieving the primary efficacy endpoint at 14 days. The company also received regulatory approvals to commence Registrational Phase 3 clinical trials assessing R327G Topical Gel for the treatment of diabetic foot infections (DFIs) in Indonesia. Additionally, the company received grant funding of US$2 million from the US Department of Defence in recognition of R327G as a topical treatment for burn wound infections, and promising results from a study on the efficacy of R327 against multidrug-resistant pathogens. The company also raised a total of A$15.8 million through a private placement and entitlement offer, and secured a debt facility of up to A$30 million from Avenue Capital Group.